Skip to main content
. 2022 Mar 30;26(1):78–87. doi: 10.5114/wo.2022.115678

Table 1.

The clinicopathological features of the entire group of patients (N = 61)

Factor
Age, years (mean ± SD) 48.0 ± 9.8
Menopausal status, n (%) Pre 27 44.30
Post 34 55.70
Body mass index (BMI), n (%) Low 11 18.00
High 50 82.00
Family history, n (%) No 55 90.20
Yes 6 9.80
Diabetes mellitus (DM), n (%) No 52 85.20
Yes 9 14.80
Pathological subtypes,
n (%)
IDC 40 65.60
IL 14 23.00
Others 7 11.50
Grade, n (%) 1 4 6.60
2 29 47.50
3 28 45.90
Capsular invasion, n (%) No 35 57.40
Yes 26 42.60
ER, n (%) Negative 26 42.60
Positive 35 57.40
PR, n (%) Negative 31 50.80
Positive 30 49.20
HER2, n (%) Negative 44 72.10
Positive 17 27.90
Ki-67, n (%) Low 44 72.10
High 17 27.90
Molecular subtypes,
n (%)
Luminal A 24 39.30
Luminal B 11 18.00
HER2 amplified 14 23.00
Triple –ve 12 19.70
T, n (%) 0 2 3.30
1 8 13.10
2 9 14.80
3 23 37.70
4 17 27.90
N, n (%) 0 10 16.40
1 17 27.90
2 5 8.20
3 29 47.50
Stage, n (%) Stage I 4 6.60
Stage II 13 21.30
Stage III 29 47.50
Stage IV 15 24.60
M, n (%) No 46 75.40
Yes 15 24.60